Market Access Strategy
Digital Health Applications
Mobilizing the Market
Medical Technology and Biotechnology
Digital Health Provider
EU5: Commercial assessment of licensed products for the five major EU markets
Conception of the German market access for two innovatice products
Consistent brand management strengthens the clients base for health delivery
Corporate vision: long-term vision of a hospital
Digital strategy and agenda combine digitization initiatives
Discharge management of a rare disease
How effective integrated care really is
Leadership strategy and executives development
Service cost management: Limiting rising hospital spending
Strategic support and negotiation lead:
Trial regulations: strategic support (pursuant to §137e SGB V)
Value assessment and value story for a digital solution
Written statement and oral hearing revise the initial benefit assessment
Vision and Approach
Prof. Matthias P. Schönermark M.D., Ph.D.
Heike Kielhorn-Schönermark, MBA
Would you like to call us?
+49 511 64 68 14 0 – 0
Would you like to visit us personally?
This is how you find our office in Hannover.
Your request via contact form
* mandatory field
Yes, I agree with the
Discover the latest news from the industry, clearly and comprehensibly presented.
Pay-for-Performance: when is a therapy successful?
Challenges in the negotiation of Pay-for-Performance contracts
World Health Day 2021
"Building a fairer, healthier world"
Exceptional times require creative solutions
An insight into our daily work life during Corona
The epidemiology of rare diseases
“Who am I – and if so, how many?”
Sixth strategic field of the of the EMA’s network strategy
Sustainability of the network and operational excellence
Fifth strategic field of the of the EMA’s network strategy
Supply chain challenges for medicinal products
Fourth strategic field of the EMA’s network strategy
Antimicrobial resistance and other emerging health threats
Research gives new insights in the development of rare diseases
An epigenetic mechanism for gene regulation described for the first time provides new insights into the development and etiology of rare diseases.
to the top